Immunis Inc., a clinical-stage biotechnology company, has partnered with Springbok Analytics to evaluate the clinical efficacy of its investigational secretome therapy, IMMUNA, in reversing sarcopenia. This collaboration is part of Immunis’ Phase 1/2a clinical trial targeting muscle atrophy in elderly individuals with knee osteoarthritis.
Sarcopenia, characterized by age-related muscle loss, significantly contributes to disability among older adults, leading to increased healthcare costs exceeding $40 billion annually in the United States alone. Despite its prevalence, there are currently no pharmaceutical interventions to prevent or treat sarcopenia.
IMMUNA is a novel therapy derived from human cell secretions, containing natural factors aimed at treating complex age-related diseases. Preclinical studies have demonstrated that IMMUNA can enhance muscle regeneration, improve strength, increase metabolism, and reduce fat.
Springbok Analytics provides MRI-based AI muscle analysis technology, which will be utilized to assess the impact of IMMUNA on muscle tissue architecture and function in clinical trial participants. Their technology offers rapid, high-resolution imaging, with lower extremity scans completed in under 10 minutes and full-body scans in less than 40 minutes.
Erin Curry, Director of Medical Affairs at Immunis, emphasized the importance of Springbok’s technology in accurately assessing clinical trial data, stating that it allows for a clearer understanding of how IMMUNA affects muscle and body changes over time.
This partnership signifies a significant step toward developing effective treatments for sarcopenia, aiming to improve the quality of life for millions affected by this condition.
